Investor Steve Wagner says he is uneasy about Novo's Q3, pointing to a Medicare price cut on Ozempic, still its top revenue driver, that began around July 1.
Recap by typeshit. Post by Steve Wagner on X.
An explainer on talking to a provider about whether Wegovy fits you, plus a reminder that insurance may not pay for it.
Khunti shares real-world data on over a million UK adults using telehealth for obesity care, where 90% started on tirzepatide before a major price hike changed prescribing.
Polskie Radio reports a Wegovy price cut in China, coming soon after the drug's approval there. Tap through for the details.
Novo Nordisk is cutting what Wegovy costs in China, Polskie Radio reports. Tap through for the size of the cut and when it takes effect.
Dr Wong says the rare vision loss linked to Ozempic is a small risk, and goes over who may be more vulnerable and which eye changes need care right away.
The tester liked the easy intake and fast shipping but wished he could have spoken with a provider before being approved.
Loading…